<?xml version='1.0' encoding='utf-8'?>
<document id="28875498"><sentence text="Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype."><entity charOffset="32-42" id="DDI-PubMed.28875498.s1.e0" text="Vonoprazan" /><entity charOffset="47-59" id="DDI-PubMed.28875498.s1.e1" text="Esomeprazole" /><entity charOffset="88-99" id="DDI-PubMed.28875498.s1.e2" text="Clopidogrel" /><entity charOffset="103-112" id="DDI-PubMed.28875498.s1.e3" text="Prasugrel" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e0" e2="DDI-PubMed.28875498.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e0" e2="DDI-PubMed.28875498.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e0" e2="DDI-PubMed.28875498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e0" e2="DDI-PubMed.28875498.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e1" e2="DDI-PubMed.28875498.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e1" e2="DDI-PubMed.28875498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e1" e2="DDI-PubMed.28875498.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e2" e2="DDI-PubMed.28875498.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s1.e2" e2="DDI-PubMed.28875498.s1.e3" /></sentence><sentence text="Drug-drug interaction between antiacid and antiplatelet agents has not been fully elucidated" /><sentence text=" Vonoprazan, a new potassium competitive acid blocker, has been available in Japan"><entity charOffset="1-11" id="DDI-PubMed.28875498.s3.e0" text="Vonoprazan" /><entity charOffset="19-28" id="DDI-PubMed.28875498.s3.e1" text="potassium" /><pair ddi="false" e1="DDI-PubMed.28875498.s3.e0" e2="DDI-PubMed.28875498.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s3.e0" e2="DDI-PubMed.28875498.s3.e1" /></sentence><sentence text=" CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan"><entity charOffset="54-65" id="DDI-PubMed.28875498.s4.e0" text="clopidogrel" /><entity charOffset="67-76" id="DDI-PubMed.28875498.s4.e1" text="prasugrel" /><entity charOffset="78-90" id="DDI-PubMed.28875498.s4.e2" text="esomeprazole" /><entity charOffset="96-106" id="DDI-PubMed.28875498.s4.e3" text="vonoprazan" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e0" e2="DDI-PubMed.28875498.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e0" e2="DDI-PubMed.28875498.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e0" e2="DDI-PubMed.28875498.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e0" e2="DDI-PubMed.28875498.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e1" e2="DDI-PubMed.28875498.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e1" e2="DDI-PubMed.28875498.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e1" e2="DDI-PubMed.28875498.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e2" e2="DDI-PubMed.28875498.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s4.e2" e2="DDI-PubMed.28875498.s4.e3" /></sentence><sentence text=" Using a P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the antiplatelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers (14 CYP2C19 homo-extensive (homo-EMs), nine hetero-extensive (hetero-EMs), and eight poor metabolizers (PMs))"><entity charOffset="49-59" id="DDI-PubMed.28875498.s5.e0" text="vonoprazan" /><entity charOffset="64-76" id="DDI-PubMed.28875498.s5.e1" text="esomeprazole" /><entity charOffset="110-121" id="DDI-PubMed.28875498.s5.e2" text="clopidogrel" /><entity charOffset="125-134" id="DDI-PubMed.28875498.s5.e3" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e0" e2="DDI-PubMed.28875498.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e0" e2="DDI-PubMed.28875498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e0" e2="DDI-PubMed.28875498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e0" e2="DDI-PubMed.28875498.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e1" e2="DDI-PubMed.28875498.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e1" e2="DDI-PubMed.28875498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e1" e2="DDI-PubMed.28875498.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e2" e2="DDI-PubMed.28875498.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s5.e2" e2="DDI-PubMed.28875498.s5.e3" /></sentence><sentence text=" Vonoprazan decreased the median inhibition of platelet aggregation (IPA) values of clopidogrel and prasugrel more potently than esomeprazole (P &lt; 0"><entity charOffset="1-11" id="DDI-PubMed.28875498.s6.e0" text="Vonoprazan" /><entity charOffset="84-95" id="DDI-PubMed.28875498.s6.e1" text="clopidogrel" /><entity charOffset="100-109" id="DDI-PubMed.28875498.s6.e2" text="prasugrel" /><entity charOffset="129-141" id="DDI-PubMed.28875498.s6.e3" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e0" e2="DDI-PubMed.28875498.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e0" e2="DDI-PubMed.28875498.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e0" e2="DDI-PubMed.28875498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e0" e2="DDI-PubMed.28875498.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e1" e2="DDI-PubMed.28875498.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e1" e2="DDI-PubMed.28875498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e1" e2="DDI-PubMed.28875498.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e2" e2="DDI-PubMed.28875498.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s6.e2" e2="DDI-PubMed.28875498.s6.e3" /></sentence><sentence text="001 for clopidogrel and P = 0"><entity charOffset="8-19" id="DDI-PubMed.28875498.s7.e0" text="clopidogrel" /></sentence><sentence text="011 for prasugrel)"><entity charOffset="8-17" id="DDI-PubMed.28875498.s8.e0" text="prasugrel" /></sentence><sentence text=" The same tendencies were observed when stratified by CYP2C19 genotype groups (P = 0" /><sentence text="004 in homo-EMs, 0" /><sentence text="033 in hetero-EMs, and 0" /><sentence text="043 in PMs)" /><sentence text=" Vonoprazan attenuated the antiplatelet function of clopidogrel more potently than esomeprazole"><entity charOffset="1-11" id="DDI-PubMed.28875498.s13.e0" text="Vonoprazan" /><entity charOffset="52-63" id="DDI-PubMed.28875498.s13.e1" text="clopidogrel" /><entity charOffset="83-95" id="DDI-PubMed.28875498.s13.e2" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.28875498.s13.e0" e2="DDI-PubMed.28875498.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s13.e0" e2="DDI-PubMed.28875498.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s13.e0" e2="DDI-PubMed.28875498.s13.e2" /><pair ddi="false" e1="DDI-PubMed.28875498.s13.e1" e2="DDI-PubMed.28875498.s13.e1" /><pair ddi="false" e1="DDI-PubMed.28875498.s13.e1" e2="DDI-PubMed.28875498.s13.e2" /></sentence><sentence text=" Esomeprazole did not affect that of prasugrel irrespective of CYP2C19 genotype"><entity charOffset="1-13" id="DDI-PubMed.28875498.s14.e0" text="Esomeprazole" /><entity charOffset="37-46" id="DDI-PubMed.28875498.s14.e1" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.28875498.s14.e0" e2="DDI-PubMed.28875498.s14.e0" /><pair ddi="false" e1="DDI-PubMed.28875498.s14.e0" e2="DDI-PubMed.28875498.s14.e1" /></sentence><sentence text="" /></document>